Abstract Describing Use of Oregovomab in Pancreatic Cancer to be Published in JCO as Part of ASCO 2018 Meeting
Published: Jun 01, 2018
Induction of CA-125 Specific Immune Response by Oregovomab Chemoimmunotherapy in Pancreatic Cancer Patients
EDMONTON, June 1, 2018 /PRNewswire/ - Oncoquest Inc. ("OncoQuest"), a privately held, cancer immunotherapy company, today announced the publication of an abstract, titled "A Phase II Study of Neoadjuvant Chemoimmunotherapy Followed by Stereotactic Radiotherapy/Nelfinavir in Patients with Locally Advanced CA125 Expressing Pancreatic Adenocarcinoma" in the Journal of Clinical Oncology 36, 2018 (Suppl; asbt.e16202) as part of the Proceedings of American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 1 to June 5, 2018, in Chicago, Illinois.
This physician sponsored clinical study was conducted at the University of Nebraska Medical Center with Dr. Chi Lin as the principal investigator, to evaluate the safety, immune response and efficacy of neoadjuvant chemotherapy with and without Oregovomab, OncoQuest's anti-CA-125 antibody followed by hypo fractionated stereotactic radiotherapy and concurrent HIV protease inhibitor, nelfinavir, in patients with locally advanced CA-125 positive pancreatic cancer. Nelfinavir has been shown in previous studies to be a potent radiosensitizer.
This proof-of-concept open label study recruited a total of 11 patients, 9 of whom received oregovomab immunization. Five patients received five cycles of oregovomab chemoimmunotherapy ("CIT") and four patients received seven cycles of CIT. All nine received stereotactic radiotherapy following their cycles of CIT. Out of the four patients receiving seven cycles of CIT, two patients developed CA125-specific IFNγ positive CD8 T cell response and survived over 28 months and 31 months, respectively, compared to a median survival of 13 months in the study. The results also showed that previously demonstrated immune response associated with CIT was not negatively impacted by use of radiotherapy.
"The data continues to support that oregovomab CIT can induce antigen specific T-cell responses in cancer patients that translate into clinical benefits. It also provides further evidence that our antibody based immunotherapy is a platform technology that can be used with different cancers that express the same cancer antigen," commented Dr. Madiyalakan, CEO of OncoQuest. "We are also continuing our study of oregovomab in both front line and recurrent ovarian cancer to identify combinations which result in demonstrable clinical benefit and will provide the basis for moving this promising treatment forward to registration."
OncoQuest is a subsidiary of Quest PharmaTech Inc. (TSXV-QPT) ("Quest"), and is a private biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. OncoQuest's technology platform includes a portfolio of tumor antigen specific monoclonal immunoglobulins including CA-125, MUC1, PSA and Her2/neu. We are developing protocols utilizing these antibodies in combination with other immune modulating drugs or drug combinations to enhance tumor specific immunity and clinical outcome.
OncoQuest's lead product is oregovomab, an anti-CA-125 antibody, for the treatment of ovarian cancer that has completed a frontline randomized controlled Phase 2 study. In addition, oregovomab is currently being studied in multiple Phase 2 clinical trials in the relapsed recurrent ovarian cancer setting as well. OncoQuest's anti-MUC1 antibody program has already undergone a Phase 1 clinical trial in breast cancer patients, and its development is being led by OncoVent Co. Ltd., OncoQuest's joint venture partner that has licensed the rights of our immunotherapeutic antibodies in the territory of Greater China. OncoQuest's next-generation products are based on immunoglobulin E licensed from UCLA, Stanford University and Advanced Immune Therapeutics, Inc. These antigen-specific monoclonal IgE antibodies are currently in preclinical development.
Additional information about OncoQuest can be found at the company's re-designed website, www.oncoquestinc.com.
Forward Looking Statements
This press release includes forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based on management's expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. The information in this release is provided only as of the date of this release and the company undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Hany S. Awadalla, Senior Vice President and Chief Financial Officer, OncoQuest Inc., Tel: (917) 817-1264, Email: firstname.lastname@example.org, Internet: www.oncoquestinc.com
SOURCE OncoQuest Inc.